Logo

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab (BGB-A317) to Treat Nasopharyngeal Cancer in China

Share this

BeiGene Reports NMPA's Acceptance of sBLA for Tislelizumab (BGB-A317) to Treat Nasopharyngeal Cancer in China

Shots:

  • The sBLA is based on P-III RATIONALE 309 trial evaluating the efficacy & safety of tislelizumab + CT vs PBO + CT in a ratio (1:1) in 263 Asian patients with recurrent or metastatic NPC
  • The 1EPs of a trial is PFS as assessed by IRC in ITT population & 2EPs includes OS- ORR- DoR- investigator-assessed PFS- the safety profile was consistent with its known risks with no new safety signals observed with an addition of CT
  • Tislelizumab is a humanized IgG4 anti-PD-1 mAb- designed to minimize binding to FcγR on macrophages. In Jan’21- BeiGene & Novartis entered into a license agreement in which Novartis got rights to develop- manufacture & commercialize the therapy in North America- EU & Japan

  | Ref: Businesswire | Image: Forbes

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions